chevron_leftBack
As of 24 April 2025, Solasia Pharma K.K. has a market cap of $50.5M USD, ranking #24685 globally and #2729 in Japan. It ranks #2505 in the Healthcare sector, and #553 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$50.5MUSD
7.2B JPY
Enterprise Value
$44.26MUSD
6.33B JPY
Revenue (TTM)
$2.22MUSD
316.0M JPY
EBITDA (TTM)
-$12.26MUSD
-1.76B JPY
Net Income (TTM)
-$13.62MUSD
-1.94B JPY
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Yoshihiro Arai
open_in_new
Employees
23
Founded
2006
Website
solasia.co.jp
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3% | -3% | -20% | -2.9% | -20% | 32% |
Upcoming Earnings
Earnings Date
Wed, May 14
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4597
ソレイジア・ファーマ株式会社
ISIN: JP3436500007
Shares Out.:
Shares Outstanding:
218.05M1
Shares Float:
188.633M2
|
32 JPY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Solasia Pharma K.K.
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso for chemotherapy induced nausea and vomiting. It also develops SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-04, which is in preclinical trial development for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.
